Therapeutic antibody surfaces

Therapeutic antibody surfaces refer to the exposed molecular landscape of monoclonal antibodies, encompassing the complementarity-determining regions (CDRs) and the framework regions. These surfaces dictate the antibody's biophysical properties, such as solubility, stability, and propensity for aggregation, which are critical for developability (Jain et al., 2017, PNAS). The surface characteristics, including charge distribution and hydrophobicity, influence the pharmacokinetic profile and the potential for immunogenicity, where the patient's immune system recognizes the antibody surface as foreign (Wang et al., 2018, Journal of Pharmaceutical Sciences). Engineering these surfaces is a central focus in biotechnology to optimize drug delivery, minimize side effects, and ensure high affinity for specific antigens (Raybould et al., 2019, PNAS). While not a therapeutic target itself, the antibody surface is the primary interface for interaction with both the intended antigen and the host's biological environment. Specific patches on the surface, such as hydrophobic regions, are often screened during drug development to avoid off-target binding and rapid clearance (Lauer et al., 2012, Journal of Pharmaceutical Sciences). The Fc region surface is particularly important for binding to Fc receptors, which mediates antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Understanding these surfaces allows for the design of next-generation biologics with improved safety profiles and longer half-lives.

Other names

Antibody surface propertiesMonoclonal antibody surfacemAb surface patchesParatope and framework surfaces

Not applicable; therapeutic antibody surfaces are structural features of drugs rather than biological targets for therapeutic intervention.